Prostate cancer is focus of bioMérieux, ProteoSys deal
This article was originally published in Clinica
Executive Summary
French diagnostics company bioMérieux is set to combine with German biotechnology research firm ProteoSys to develop a urine-based confirmatory diagnostic for prostate cancer. The test will use the Annexin 3 biomarker, discovered by Mainz-based ProteoSys, and will be developed to run on bioMérieux’s Vidas analyser platform after an initial research phase. According to bioMérieux, when used alongside standard screening methods, the new test “could potentially reduce the number of biopsies conducted by up to 75%”. Financial details of the deal were not disclosed.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals